Vol. 8, Issue 1, Part A (2026)

Alzheimer’s disease (AD) remains a major challenge in neurodegenerative disorder management, with limited treatment options available. This study investigates Liquiritin, a bioactive compound from Glycyrrhiza glabra, for its potential as an anti-Alzheimer’s agent. Molecular docking simulations were conducted with the amyloid beta-protein precursor (PDB ID: 1AAP), comparing Liquiritin with Donepezil. Liquiritin exhibited a MolDock score of -103.59, indicating comparable or stronger binding affinity than Donepezil, with a higher Rerank score and stronger hydrogen bond interactions. The results suggest that Liquiritin could offer a promising alternative for Alzheimer’s treatment. These findings support the need for further experimental validation of Liquiritin’s neuroprotective effects.